Author(s): Mohsen Akhondi-Meybodi, Masoud Rahimian, Hasan Salmanroghani, MohammadKazem Amirbeigy, Mahmoud Baghbanian, SeydYaser Ghelmani
"Irritable bowel syndrome is the most common diagnosed gastro enteric disorder incriminated for 12% of cases of referring to gastroenterologists. Various studies have shown that the intestinal micro flora of the patients affected with IBS undergoes some changes. Therefore, it seems that the recovery of intestinal flora is a useful therapeutic approach. This study investigated the effect of probiotic Saccharomyces Boulardii on improving the symptoms of IBS. This study was a randomized double-blind clinical trial conducted on 60 IBS patients. The patients were divided into two groups of 30 (case and control groups). The patients in the case group received Yomogi and those in the control group got placebo. Demographic information and symptoms as abdominal pain, flatulence, diarrhea, constipation, gurgling, eructation (belching and burping), urgent defecation, and release of gas from the anus (farting and fizzling) were collected before intervention and three weeks after initiation of treatment, and analyzed. 43.3% of the patients in the case group were male and 56.7% were female. In addition, 40% of the patients in the control group were male and 60% were female. A comparison of the mean scores of abdominal symptoms in the case group before and after intervention revealed that there was a statistically significant difference between before and after intervention values for pain severity (P=0.001), flatulence (P=0.001), diarrhea (P=0.001), gurgling (P=0.001), eructation (P=0.023), and gas release from the anus (P=0.001). Yet, there was no statistically significant difference before and after intervention for symptoms of constipation (P=0.161), and urgent defecation (P=0.09). The consumption of Saccharomyces Boulardii reduces pain severity, flatulence, diarrhea, gurgling, eructation, and gas release from the anus in patients with IBS and improves life quality."
Share this article